Publisher's Synopsis
This monograph contains the proceedings of a conference devoted to progress and emerging issues in therapeutic cancer vaccine development since the 1998 FDA/NCI workshop. The emphasis is on progress in the clinical trials of cancer vaccines in late-stage development, but the volume also includes presentations and discussions on exciting earlier-stage products as well as updates on regulatory positions in the USA, Canada, Europe, and Australia. Session I concentrates on regulatory considerations in cancer vaccine development, including a round table of regulatory agency representatives from North America, Europe, and Australia. Session II continues with a consideration of several different types of cancer vaccines, including whole cells, cell lysates, multivalent recombinants and peptides. Session III highlights dendritic cell vaccines and dendritic cells fused to tumour cell vaccines. Session IV focuses on preventive cancer vaccines for cervical carcinoma and liver cancer and various aspects of the immune response to cancer vaccines.
